DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
about
Overview of current immunotherapeutic strategies for gliomaBiomarkers for glioma immunotherapy: the next generationSui generis: gene therapy and delivery systems for the treatment of glioblastomaDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsTargeting immune checkpoints in malignant gliomaDendritic Cell-Based Immunotherapy Treatment for Glioblastoma MultiformeMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patientsImmunocompetent murine models for the study of glioblastoma immunotherapySensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategyOverview of cellular immunotherapy for patients with glioblastoma.In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imagingCryo-ablation improves anti-tumor immunity through recovering tumor educated dendritic cells in tumor-draining lymph nodes.Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.Recent developments on immunotherapy for brain cancer.Assessment of bystander killing-mediated therapy of malignant brain tumors using a multimodal imaging approachIrradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Immune-checkpoint blockade and active immunotherapy for glioma.Glioma stem cell research for the development of immunotherapy.Wilms' Tumour gene 1 (WT1) as an immunotherapeutic targetExperimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.Immunotherapy targeting glioma stem cells--insights and perspectives.Cancer immunoediting in malignant glioma.Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.Brain Tumor Immunotherapy: What have We Learned so Far?Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future.Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.Controlling and monitoring stem cell safety in vivo in an experimental rodent model.In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models.Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy.Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain.Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.Treg infiltration in glioma: a hurdle for antiglioma immunotherapy.Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production.
P2860
Q26776345-867C2D24-8757-4047-9CB6-B2440096A398Q26825496-A4E15690-82D3-4887-A77A-79AF6767C7A3Q26850467-49808F0E-1C98-482A-BFE5-FF33089A6858Q27014829-06A8D6C7-B98F-4A9D-9FE1-17286602FD3AQ28072012-124B6891-14BD-4E37-8ED3-3F167B79B68FQ28087485-2C3FF245-BA38-4FD8-962F-14CD471FA039Q28730798-ED7BF98B-8961-4593-83E4-9CCA9551D3A5Q33574853-0A4AA189-AFBC-4103-822C-824F974460A6Q33683101-0070345D-5760-43D1-B6A4-959193249F33Q34189694-660639CF-355D-437E-8DB8-BDF6ADCAE92AQ34716748-A4F28961-3D29-4202-AED2-4ECB94332286Q35184986-23B57029-0BD2-4CEE-AE74-D13C994833C6Q35561280-EA66AB0A-2CCC-4B55-9597-41CAF71F1CC8Q35992355-D69A85A9-E546-46B8-848D-7E33769E04EEQ36035112-BA585B2B-9A2B-4631-BBE4-8DA3FE3D7A4FQ36710917-99A17294-E605-4B3F-9CF1-713C4BEAA23CQ37420586-FC807864-44B2-4279-83B1-E9E0609F301CQ37452665-BCB3C9FE-72B6-4C55-A2D8-E58C811E4AA0Q37704104-DE4627D2-F964-4E91-A307-1E1F6C8B707BQ37814208-974CA2AE-5FF2-4215-8591-362153B0D5FEQ37971408-44930E0B-DA05-4702-BA7E-D3E1C120ECAFQ37986999-B5CF6F08-CECE-4688-8324-EACFB959CEF5Q38002844-9309E050-FF3A-444B-B24D-6A9ADDCF4923Q38110540-45307533-FC79-48C4-A606-55A13A7536F3Q38176625-89C1992B-2B2A-45F0-AAFB-49682D4F024CQ38438763-AD752C1D-EB4C-4C50-BD31-31E3B9D5E3E2Q38542113-62DC4901-B1B8-4D3E-9FF8-F08F64AF700DQ38691679-9A267A88-DAB9-40ED-97DC-BEE941C03BB0Q38809194-FE9A516E-98CB-4BA0-BC9D-910D69327B94Q38912265-92298E62-F6A9-4EAA-B986-93961360938EQ38925761-7AF89B14-DA6B-411B-9437-382949CD93FAQ38964198-59B272C3-1B45-4ADE-B5E4-B307207C77ECQ38978515-7D63B310-FF9B-465D-81FF-19634987EF4CQ39161026-53793432-F09D-43BB-9286-61ADDE0C05AAQ40752470-78FE0E63-C188-48ED-AFAC-46A9BE81314AQ40982444-4E4DDA80-6B6B-40AB-9005-727ED95B3EA2Q41744540-18621AF1-C4C9-43D8-8517-D0A38C6FA3BCQ42639856-237A3171-B39F-4CE8-9B7D-8ADE54EE5959Q44315396-173E86EE-39DE-4C44-B407-4859AF25900BQ44626008-20285345-DCDF-4C66-9284-30F09905032D
P2860
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
DC vaccination with anti-CD25 ...... y against experimental glioma.
@en
DC vaccination with anti-CD25 ...... y against experimental glioma.
@nl
type
label
DC vaccination with anti-CD25 ...... y against experimental glioma.
@en
DC vaccination with anti-CD25 ...... y against experimental glioma.
@nl
prefLabel
DC vaccination with anti-CD25 ...... y against experimental glioma.
@en
DC vaccination with anti-CD25 ...... y against experimental glioma.
@nl
P2093
P2860
P1433
P1476
DC vaccination with anti-CD25 ...... ty against experimental glioma
@en
P2093
Bert Verbinnen
Georgina Galicia Rosas
Louis Boon
Stefaan W Van Gool
P2860
P304
P356
10.1215/15228517-2009-004
P577
2009-03-31T00:00:00Z